SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XFloki is a meme-inspired cryptocurrency project launched on the Ethereum network, themed around Elon Musk’s pet dog, who is humorously referred to as the “CEO of X.” The project aims to merge meme culture, blockchain technology, and community engagement through a decentralized platform that highlights entertainment, creativity, and innovation in Web3. XFloki distinguishes itself by combining Ethereum-based smart contracts with a strong narrative centered on Elon Musk’s symbolic leadership of X through his dog, Floki. It integrates interactive website features, governance participation, and token utility, offering the community a structured yet entertaining ecosystem rooted in transparency and decentralization.

NEW X CEO IS BACK

The community is expressing significant skepticism and frustration regarding liquidity concerns and the legitimacy of recent token listings, with many investors cautioning others about potential traps in the ecosystem.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is generating significant discussion as investors weigh the project's institutional privacy ambitions against concerns regarding its decentralized rollout and heavy Google Cloud involvement. While some in the community see the integration with traditional banking and robust ZK-proof technology as a long-term catalyst, others remain skeptical, frequently drawing comparisons to broader Cardano ecosystem volatility and past airdrop distribution challenges.

SLEEPLESS COIN

The community is debating whether this Solana-based project is a sustainable investment or another high-volatility pump-and-dump scheme amidst broader market uncertainty. Discussions center on comparing the asset to other meme coins and questioning its long-term viability despite current social media momentum.

HSBC Holdings Plc engages in the provision of banking and financial services. It operates through the following business segments: Hong Kong, the United Kingdom (UK), Corporate and Institutional Banking (CIB), International Wealth and Premier Banking (IWPB), and Corporate Centre. The Hong Kong segment consists of retail banking and wealth and commercial banking of HSBC Hong Kong and Hang Seng Bank. The UK segment covers UK personal banking and commercial banking, including HSBC Innovation Bank. The CIB segment was formed from the integration of the commercial banking business outside the UK and Hong Kong with the global banking and markets business. The IWPB segment refers to premier banking outside of Hong Kong and the UK, the Private Bank, and wealth manufacturing businesses of asset management and insurance. The Corporate Centre segment is involved in central treasury, including balance sheet management, other legacy businesses, interests in associates and joint ventures, central stewardship costs, and the UK bank levy. The company was founded on January 1, 1959 and is headquartered in London, the United Kingdom.

HSBC Holdings plc - ADR

HSBC Holdings plc

HSBC is trending following reports that it is weighing a significant, multi-year AI-driven restructuring plan that could result in the reduction of up to 10% of its global workforce. While the bank recently reported a 41% revenue surge in its latest quarterly results, investors are actively debating the long-term feasibility of using generative AI to permanently scale back middle and back-office operations without compromising service.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is trending as investors monitor ongoing project development and anticipate a major tenant announcement, with sentiment heavily influenced by the firm's strategic positioning in the high-demand AI infrastructure and data center energy sector. The community is actively debating the significance of recent financing milestones, management's ability to secure large-scale contracts, and potential volatility stemming from lock-up expirations and legal headwinds.

Dogelon Mars

Dogelon Mars continues to trend on social platforms as the community maintains its strong, long-term commitment, often discussing the potential for a future breakthrough despite recent volatility. Supporters frequently compare the token's persistent branding and market cap to other major meme coins, viewing it as an overlooked project with high speculative potential.

Kaspa was fair-launched in November 2021 with no pre-mine, zero pre-sale, and no coin allocations, and is 100 percent community-managed. Kaspa aims to be the world's global sequencer for traditional finance and decentralized crypto markets by utilizing proof-of-work and its BlockDAG consensus protocol, GHOSTDAG. Being the world's fastest proof-of-work network, Kaspa combines five properties: (1) hard money principles, (2) Bitcoin's ethos of security-first fundamentals (boasting a security threshold of fifty percent with significant market hashrate), (3) decentralization from rapid block rate mining, (4) block speeds faster than any PoW or PoS network, and (5) smart contract development through based-rollups without fragmented liquidity. Ushering in all five properties, Kaspa is on track to fulfill Satoshi Nakamoto's vision of a digital medium of exchange while also advancing global layer-one sequencing and minuscule confirmation times dominated by internet latency (cf. chapter 6 of the the paper for some initial benchmarks). The Kaspa implementation includes a lot of cool features and subprotocols including Reachability to query the DAG's topology, Block data pruning (with near-future plans for block header pruning), SPV proofs, and later subnetwork support which will make future implementation of layer 2 solutions much easier.

Kaspa

Kaspa is currently trending as investors debate the impact of upcoming smart contract integrations and the potential for tier-one exchange listings to drive future value. Community sentiment remains deeply divided, with long-term holders emphasizing the project's technical scalability and Proof-of-Work fundamentals, while critics point to stagnant price action and the lack of major exchange accessibility as primary concerns.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin continues to experience intense volatility as traders debate the long-term impact of AI-driven ad tech versus competitive threats from major industry incumbents. While bulls point to high-profile analyst upgrades and robust growth in its AXON platform as evidence of a structural moat, the stock remains a primary target for aggressive short-selling campaigns and broader market sentiment shifts.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is seeing significant investor attention driven by anticipation of the CVS Caremark Tier 1 formulary switch and ongoing recruitment efforts to expand its sales force. The community is actively discussing the potential for a short squeeze and long-term valuation growth, while expressing optimism that the companys ophthalmic platform will demonstrate accelerating revenue momentum heading into the new year.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing extreme volatility as retail investors scramble to gain exposure to high-profile private tech companies like Anthropic and SpaceX, leading to intense debates over whether the fund's massive valuation premium is justified or an unsustainable bubble. Community sentiment is deeply polarized, with many investors holding shares for long-term venture access while others warn of a looming crash as short-sellers face significant difficulty finding borrowable shares.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by Brokerages

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has earned an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the firm, Marketbeat Ratings...

4D Molecular Therapeutics (NASDAQ:FDMT) Sees Unusually-High Trading Volume - Here's Why

4D Molecular Therapeutics (NASDAQ:FDMT) Sees Large Volume Increase - Here's What Happened...

4D Molecular Therapeutics (NASDAQ:FDMT) Trading 8.7% Higher - Here's Why

4D Molecular Therapeutics (NASDAQ:FDMT) Trading 8.7% Higher - Here's What Happened...

Research Analysts Issue Forecasts for FDMT FY2030 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Investment analysts at HC Wainwright issued their FY2030 earnings estimates for shares of 4D Molecular Therapeutics in a research note issued on Friday, March 20th. HC Wainwright analyst M. Caufield forecasts that the company will earn...

4D Molecular Therapeutics (NASDAQ:FDMT) Raised to "Hold" at Wall Street Zen

Wall Street Zen raised shares of 4D Molecular Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...

4D Molecular Therapeutics' (FDMT) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated a "buy" rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Friday...

4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up After Analyst Upgrade

4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up After Analyst Upgrade...

4D Molecular Therapeutics (NASDAQ:FDMT) Given New $35.00 Price Target at Royal Bank Of Canada

Royal Bank Of Canada raised their price target on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an "outperform" rating in a research note on Thursday...

Chardan Capital Reiterates "Buy" Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

Chardan Capital restated a "buy" rating and set a $26.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday...

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of +180.75% and +147.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

4D Molecular Therapeutics Inc

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

FDMT
4D Molecular Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest FDMT News

FDMT4D Molecular Therapeutics Inc